Clinical Trial Search

Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants

Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…

Primary: Percentage of Participants by ESA Types at Baseline — 51.5; 17.3; 10.7; 20.4 percentage of participants

Primary: Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52) — 1.02; 1.12 Grams per deciliter

Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…

Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)…

Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…

Primary: Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28) — 0.19; 1.58 Grams per deciliter — p=<0.0001

Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971

Primary: Mean Change in Hb Concentration g/dL Between Baseline and the Efficacy Evaluation Period — 1.75 g/dL

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants

Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants

Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001

Primary: Mean Change From Baseline in Hemoglobin (Hgb) on Day 29 — 9.91; 0.63 Grams per decilitre (g/dL) — p=0.0020

Primary: Summary of Hemoglobin (Hgb) Concentration at Week 24 — 10.20; 10.64; 10.03; 10.66 grams per deciliter

Primary: Number (%) of Participants With an Hb Response by Week 17 — 19; 24; 21; 23 Participants

Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036

Primary: Mean Height of Participants at Baseline (Week 0) — 163.15 cm

Primary: Change in Hemoglobin (Hgb) — 0.6; 0.2 g/dL

Primary: Percentage of Participants With Hemoglobin (Hb) Response — 94.12; 93.51 percentage of participants — p=<0.0001

Primary: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) — 9.46; 9.93; 9.86; 9.67 Grams per deciliter (g/dL) — p=<0.0001

Primary: Percentage of Participants in Receipt of 1 or More RBC Transfusions — 24.40; 24.14 Percentage of Participants

Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — 4.695; 4.641 gram per liter

Primary: Baseline Hemoglobin Concentration — 10.3; 10.4 g/dL

Primary: Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline — 22.8 Percentage of participants

Primary: Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks) — 0.3; 0.9 g/dL — p=.0062

Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — -3.25; 3.5; -2.75 g/L

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 9.34; 9.20; 9.07; 11.45 g/dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.02; 10.03; 10.03; 11.55 g/dL

Primary: Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52) — -0.04; 0.02 Grams per deciliter (g/dL)